Enliven Therapeutics (ELVN) was recently removed from several Russell indexes, including the Russell Microcap and Russell 3000E group. This index reshuffle can influence index fund flows and short term trading dynamics for the stock.

Despite the index removals, Enliven Therapeutics has seen strong momentum recently, with a 30 day share price return of 51.17%, a year to date share price return of 227.16%, and a 1 year total shareholder return of 135.59% that points to longer term investors already experiencing substantial gains.

If recent biotech volatility has you thinking about diversification, this could be a good moment to scan for other opportunities in healthcare focused AI stocks via the 40 healthcare AI stocks.

After that index exit and rapid share price move, Enliven Therapeutics still trades about 28% below the average analyst target of US$65.11. Is that a cautious market correctly pricing risk or a discount worth examining more closely?

Preferred Price to Book Multiple of 7.8x: Is it justified?

On a simple yardstick, Enliven Therapeutics trades on a P/B ratio of 7.8x, which sits well above the broader US pharmaceuticals industry average of 2.4x.

The P/B ratio compares the company’s market value to its book value, which is essentially net assets on the balance sheet. For a clinical stage biotech with no meaningful revenue and a reported net loss of $98.78m, investors are often paying for future trial outcomes and potential commercial pipelines rather than current earnings or cash flows.

That premium P/B multiple suggests the market is assigning a high value to Enliven Therapeutics' pipeline and growth forecasts even though analysts expect the company to remain unprofitable over the next three years, with earnings forecast to decline on average by 15.1% per year.

The gap to the industry is clear, with Enliven Therapeutics' 7.8x P/B multiple more than three times the US pharmaceuticals average of 2.4x. This points to a much richer valuation than many peers.

Result: Price to book ratio of 7.8x (OVERVALUED)

However, Enliven Therapeutics still carries clear risks, including ongoing net losses of $98.78m, and clinical trial outcomes for ELVN-001 and ELVN-002 that remain uncertain.

Next Steps

With Enliven Therapeutics attracting both enthusiasm and concern, this is a moment to look at the numbers yourself and decide where you stand. For a clearer view of the trade off between potential upside and the key issues on investors’ minds, start with the 2 key rewards and 4 important warning signs.

Looking for more investment ideas beyond Enliven Therapeutics?

If Enliven Therapeutics has sharpened your interest, do not stop here. Broaden your watchlist with other stocks that fit clear, evidence based criteria using the Simply Wall Street Screener.

• Target steadier compounding potential by focusing on companies that combine earnings quality with attractive pricing through the 44 high quality undervalued stocks.
• Prioritise resilience by zeroing in on businesses with strong balance sheets and fundamentals using the solid balance sheet and fundamentals stocks screener (47 results).
• Spot early stage opportunities that might sit off most investors’ radar by working through the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.